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Diamond-Blackfan anemia (DBA) is characterized by
anemia and cancer susceptibility and is caused by
mutations in ribosomal genes, including RPL11.
Here, we report that Rpl11-heterozygous mouse em-
bryos are not viable and that Rpl11 homozygous
deletion in adult mice results in death within a few
weeks, accompanied by bonemarrow aplasia and in-
testinal atrophy. Importantly, Rpl11 heterozygous
deletion in adult mice results in anemia associated
with decreased erythroid progenitors and defective
erythroid maturation. These defects are also present
in mice transplanted with inducible heterozygous
Rpl11 bone marrow and, therefore, are intrinsic to
the hematopoietic system. Additionally, heterozy-
gous Rpl11 mice present increased susceptibility to
radiation-induced lymphomagenesis. In this regard,
total or partial deletion of Rpl11 compromises p53
activation upon ribosomal stress or DNA damage in
fibroblasts. Moreover, fibroblasts and hematopoietic
tissues from heterozygous Rpl11 mice present
higher basal cMYC levels. We conclude that Rpl11-
deficient mice recapitulate DBA disorder, including
cancer predisposition.INTRODUCTION
The ribosomal protein L11 (RPL11) is one the most relevant and
extensively studied ribosomal proteins. Interest in this protein
has notably increased during the last years because of its con-
nections with Diamond-Blackfan anemia (DBA) and with onco-
genic pathways. In particular, a subset of Diamond-Blackfan
anemia (DBA) patients carry loss-of-function haploid mutations
in the RPL11 gene (Boria et al., 2010; Cmejla et al., 2009; Gazda
et al., 2008; Quarello et al., 2010). Mutations in several other ribo-
somal proteins also produce DBA, being RPS19 the most
frequently mutated gene in DBA (Boria et al., 2010). DBA is a712 Cell Reports 13, 712–722, October 27, 2015 ª2015 The Authorscongenital diseasemainly characterized by amoderate to severe
anemia and by increased susceptibility to cancer (Narla and
Ebert, 2010; Teng et al., 2013). A major feature of the red blood
cell aplasia in DBA patients is a reduction in erythroid progenitors
and impaired erythroid maturation (Miyake et al., 2008; Moniz
et al., 2012). In addition, mutations in RPL11 are associated
with characteristic thumb malformations (Gazda et al., 2008).
Beyond its function as part of the ribosome, ribosome-free
RPL11 activates p53 through the so-called ribosomal/nucleolar
stress pathway. Specifically, conditions that perturb ribosome
biogenesis, such as certain DNA damaging agents or cMYC
overexpression, result in ribosome-free RPL11, which binds to
and inhibits MDM2, thereby stabilizing p53 (Bhat et al., 2004;
Bursac et al., 2012; Donati et al., 2013; Lohrum et al., 2003; Ma-
cias et al., 2010; Zhang et al., 2003b). This pathway has received
additional support by the recent resolution of the 3D structure of
the RPL11/MDM2 complex (Zheng et al., 2015). Another
emerging role of ribosome-free RPL11 is to decrease the levels
and activity of cMYC. This has been reported to occur through
binding of RPL11 to the cMYC mRNA and recruitment of the
RISC complex (Challagundla et al., 2011) and also by direct bind-
ing of RPL11 to cMYC protein and competition with transcrip-
tional coactivators (Dai et al., 2007, 2010). Therefore, ribosome-
freeRPL11may be part of a tumor suppressive response through
its combined ability to activate p53 and inhibit cMYC.
Work in zebrafish has demonstrated that inhibition of RPL11
recapitulates DBA anemia (Danilova et al., 2011; Zhang et al.,
2013). However, there are no mouse models of RPL11 defi-
ciency. Here, we have generated mice with an inducible Rpl11-
null allele, and we show that heterozygous loss of Rpl11 in adult
mice recapitulates DBA, including a higher predisposition to
cancer. We present evidence suggesting that impaired p53
activity and abnormally high levels of cMYC could underlie the
cancer susceptibility associated with Rpl11 deficiency.
RESULTS
Rpl11 Heterozygosity Cannot Sustain Embryonic
Development
To evaluate the impact of Rpl11 deficiency in vivo, we generated
a conditional knockout mouse model in which deletion of the
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Figure 1. Diploid Rpl11 Is Required for
Embryo Development and Complete Loss
of Rpl11 Severely Compromises Cell
Proliferation
(A) Scheme of the wt (+), lox, and delta (D) Rpl11
alleles. Upon Cre recombinase activation, exons 3
and 4 of the Rpl11lox allele are excised resulting in
the Rpl11D allele where exon 2 is spliced out-of-
frame with exon 5.
(B) Observed and expected Mendelian ratios for
viable genotypes. The Cre recombinase used is
under a strong synthetic promoter (CAG), being
expressed constitutively and ubiquitously in the
organism from early developmental stages.
(C) Immunoblot analysis of RPL11 protein levels in
cytosolic (C) and nuclear (N) fractions from
immortalized MEFs of the indicated genotypes,
bearing the Tg.hUbC-CreERT2 transgene, in the
absence or presence of 4OHT for 72 hr. GAPDH
and LAMIN A/C were used as cytosolic and nuclear
markers, respectively. Similar results were ob-
tained with two additional clones per genotype.
(D) Northern blot analysis of 32S and 12S rRNA
precursors in immortalized MEFs as in (C). A probe
specific for the ITS2 region was used to detect
rRNA intermediates. The mature 28S and 18S
forms were visualized by ethidium bromide stain-
ing. Similar results were obtained with two addi-
tional clones per genotype.
(E) Quantification of EdU-labeled cells in Rpl11+/+,
Rpl11+/lox, and Rpl11lox/lox primary MEFs, bearing
the Tg.hUbC-CreERT2 transgene, grown in the
absence or presence of 4OHT for 72 hr. For each
genotype, the percentage of EdU+ cells was
normalized to the untreated cells (set as 100%).
Data correspond to the average±SDof two to three
independent MEF clones per genotype. Statistical t
test analysis was performed to calculate signifi-
cance (*p < 0.05, **p < 0.01). See also Figure S1.Rpl11 gene can be controlled by theCre recombinase (Figure 1A;
Figures S1A–S1F). We first crossed Rpl11+/lox mice with a ubiq-
uitous Cre recombinase (Tg.pCAG-Cre) constitutively expressed
from early developmental stages (Sakai and Miyazaki, 1997).
However, we could not detect any Rpl11+/D pup in the offspring
of these animals (Figure 1B). Therefore, a single gene dose of
Rpl11 is not sufficient to support embryonic development.
Rpl11 Deficiency Impairs rRNA Processing and Cellular
Proliferation
To bypass the lethality of Rpl11+/D embryos, we combined the
Cre-excisable Rpl11 allele (Rpl11lox) with a ubiquitous tamox-
ifen-inducible Cre transgene (Tg.UbC-CreERT2 (Ruzankina
et al., 2007)). We isolated mouse embryonic fibroblasts (MEFs)
at E13.5 from embryos of the three relevant Rpl11 genotypes
(+/+, +/lox, lox/lox) carrying transgenic Cre in hemizygosity,
and treated them with 4-hydroxy-tamoxifen (4OHT). First, we
evaluated whether Cre activation in Rpl11+/lox and Rpl11lox/lox
cells resulted in a measurable reduction in RPL11 protein levels.
After 3 days of treatment with 4OHT, RPL11 was essentially un-
detectable in the nuclear fraction of 4OHT-Rpl11lox/lox cells, and
its levels were dramatically reduced in the cytoplasmic fraction
(Figure 1C). In the case of 4OHT-Rpl11+/lox cells, there was a par-Ctial, but clear, reduction in RPL11 levels both in the nuclear and in
the cytoplasmic fractions (Figure 1C). RPL11 participates in the
maturation of rRNA precursors and, particularly, in the process-
ing of the 32S and 12S precursors into mature 28S and 5.8S
rRNAs, respectively (Gazda et al., 2008; Robledo et al., 2008;
Sloan et al., 2013). To assess the functional impact ofRpl11 defi-
ciency, we measured the levels of 32S and 12S rRNA precursors
by northern blotting. Of note, we observed a remarkable accu-
mulation of the 32S and 12S precursors in 4OHT-Rpl11lox/lox
cells (Figure 1D). Accumulation of these precursors was also
evident in 4OHT-Rpl11+/lox cells albeit at lower levels than in
4OHT-Rpl11lox/lox cells (Figure 1D). These observations were
paralleled by a severe reduction of proliferation in 4OHT-
Rpl11lox/lox cells and a partial reduction in 4OHT-Rpl11+/lox cells
(Figure 1E). Therefore, deletion of Rpl11 in cells impairs rRNA
processing and cell proliferation, being the effects severe upon
total Rpl11 deletion and moderate upon heterozygous deletion.
Deletion of Rpl11 in Adult Mice
To test the impact of RPL11 elimination in adult organisms, mice
of the three relevant genotypes (Rpl11+/+, Rpl11+/lox, and
Rpl11lox/lox, all carrying the Tg.UbC-CreERT2 transgene in hemi-
zygosity) were fed a tamoxifen (TAM) diet starting 1.5–2 monthsell Reports 13, 712–722, October 27, 2015 ª2015 The Authors 713
Figure 2. Adult Homozygous Deletion of
Rpl11 Is Lethal and Is Associated with Intes-
tinal Atrophy and Bone Marrow Aplasia
(A) Rpl11 mRNA levels measured by qRT-PCR in
different tissues of TAM-mice of the indicated
genotypes. Data correspond to +/+ or +/lox
treated with TAM for 8 weeks (n = 4–5) or lox/lox
treated with TAM for 1 week (n = 2). b-actin
mRNA levels were used as an endogenous
control.
(B) Northern blot analysis of 32S and 12S rRNA
precursors in spleens of two animals of each
genotype fed with TAM for 1 week. A probe
specific for the ITS2 region was used to detect
rRNA intermediates. The mature 28S and 18S
forms were visualized by ethidium bromide
staining.
(C) Kaplan-Meyer survival curve for TAM-treated
Rpl11+/+, Rpl11+/lox, and Rpl11lox/lox animals. Log-
rank (Mantel-Cox) test was performed to calcu-
late significance of Rpl11lox/lox relative to the two
other groups of mice (**p % 0.01).
(D) Representative histological sections of intes-
tine stained with H&E from TAM-Rpl11+/+ and
TAM-Rpl11lox/lox animals after 1 week of treat-
ment. A total of three animals per genotype were
analyzed. Scale bars, 200 mm.
(E) Representative histological sections of bone
marrow stained with H&E. A total of two animals
per genotype were analyzed. Scale bars, 100 mm.
(F) Representative histological sections of bone
marrow stained with TER119. A total of two ani-
mals per genotype were analyzed. Scale bars,
100 and 25 mm in the top and bottom images,
respectively.
(G) Representative histological sections of spleen
(left) and liver (right) from TAM-Rpl11lox/lox animals
showing accumulation of hemosiderin (spleen)
and iron aggregates (Perls’ Prussian blue staining
in liver).
Scale bars, 100 and 25 mm in the images and zoom, respectively, in the spleen sections, and 25 mm in the liver sections. In (A), values correspond to the
average ± SD. Statistical t test analysis was performed to calculate significance (*p% 0.05; **p% 0.01; ***p% 0.005). For (C), see legend. See also Figure S2.of age. Deletion of the Rpl11lox allele was detected in the
genomic DNA of the tail (Figure S2). More importantly, Rpl11
mRNA levels were markedly reduced in TAM-Rpl11lox/lox mice
(remaining levels in the range of 5%–30% depending on the tis-
sue) and partially reduced in TAM-Rpl11+/lox mice (remaining
levels in the range of 60%–75%) (Figure 2A). Of relevance,
Rpl11 reduction had a detectable impact on the maturation of
rRNA as reflected by a clear accumulation of 32S and 12S
rRNA precursors in the spleen of Rpl11+/lox and Rpl11lox/lox
mice after 1 week of TAM treatment (Figure 2B). Therefore,
mice carrying the inducible Rpl11lox allele constitute a suitable
model for the analysis of the in vivo effects of RPL11 deficiency
in a mammalian organism.
Adult Homozygous Deletion of Rpl11 Is Lethal
Treatment of mice with TAM starting at 1.5 months of age re-
sulted to be lethal in the case of Rpl11lox/lox mice with no animals
surviving beyond 8 weeks of TAM treatment (Figure 2C). Upon
extensive histological analyses, the most obvious defects in
these mice consisted in intestinal atrophy (which probably714 Cell Reports 13, 712–722, October 27, 2015 ª2015 The Authorscaused malnutrition) and bone marrow aplasia (Figures 2D and
2E). This suggests that highly proliferative tissues are the first
to manifest defects upon severe reduction of RPL11. At the
time of death, TAM-Rpl11lox/lox mice presented signs of devel-
oping anemia, including a pronounced decrease in bone marrow
(BM) erythroblasts, as measured by nucleated TER119+ cells
(Figure 2F), and a noticeable accumulation of hemosiderin in
the spleen and iron in the liver, both consistent with defective
erythropoiesis (Figure 2G). Therefore, complete loss of Rpl11 is
lethal in adult mice, probably due to intestinal atrophy, and it is
accompanied by erythropoietic defects.
Adult HeterozygousDeletion ofRpl11Results in Chronic
Anemia
Continuous TAM treatment of Rpl11+/lox mice did not compro-
mise viability, at least during the first year of life (Figure 2C).
DBA patients typically present macrocytic anemia (Ruggero
and Shimamura, 2014), consisting in reduced red blood cell
(RBC) counts with increased cellular size (mean corpuscular vol-
ume or MCV). Considering the involvement of human RPL11
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Figure 3. Rpl11 Deficiency in Adult Mice Leads to Anemia and
Reduction of Erythroid Progenitors
(A) Red blood cell (RBC) values for Rpl11+/+ and Rpl11+/lox mice in TAM diet.
Mice were fed TAM diet at 6 weeks of age. Data correspond to the average ±
SD of six (Rpl11+/+) or seven (Rpl11+/lox) animals. Statistical t test analysis
was performed per time point to calculate significance. Differences between
genotypes were significant (*p % 0.05 or **p % 0.01) starting from 12 weeks
of TAM treatment and beyond.
(B) Representative images of TER119-stained histological sections of
bone marrows from mice that were TAM-treated during 8 (upper panel) or 20
(bottom panel) weeks. Zoom in pictures shows nucleated TER119+ cells. Scale
bars, 100 and 25 mm in the images and zoom in pictures, respectively.
Quantification of the positive area for nucleated cells expressing TER119 is
shown. Data correspond to 8 weeks (n = 3 independent mice per genotype) or
20 weeks (n = 4) of TAM treatment.
Cheterozygous mutations in DBA, we examined TAM-Rpl11+/lox
mice for signs of anemia. Interestingly, TAM-Rpl11+/lox mice
had lower RBC levels and macrocytosis compared to TAM-
Rpl11+/+ animals, being these effects more pronounced as ani-
mals aged (Figure 3A; Figure S3A). Histological examination of
the BM indicated a significant decrease in the number of eryth-
roblasts, as measured by nucleated TER119+ cells (Figure 3B).
In support of this, the total mRNA levels of genes involved in
erythrocyte function (Epor, Hbb-h1, Trfc, Alas2, and Ireb2)
were all decreased in TAM-Rpl11+/lox BM (Figure S3B). Further-
more, we observed higher levels of erythropoietin (Epo) mRNA
levels in the kidney, which is indicative of a compensatory
response to stimulate eythropoiesis (Figure 3C). Despite the pro-
nounced decrease in erythroblasts, the BM of TAM-Rpl11+/lox
mice was histologically normocellular (Figure S3C) and had
normal ratios of hematopoietic stem cells (HSCs, Lin-Sca+cKit+)
and progenitor cells (Figure S3D). Also, the sub-populations of
thymic T cells and splenic B cells were all normal in TAM-
Rpl11+/lox mice (data not shown). We conclude that partial loss
of Rpl11 produces a non-lethal anemia as a result of reduced
erythropoiesis.
Direct Involvement of Rpl11 in Erythropoiesis
To test if the BM precursors of TAM-Rpl11+/lox mice had a cell-
autonomous defect in erythropoiesis, we first tested the capacity
of BM cells to form in vitro burst-forming units-erythroid progen-
itors (BFU-E). We observed a tendency toward decreased
BFU-E in the TAM-Rpl11+/lox BM (Figure S4A). To demonstrate
that RPL11 plays a cell-autonomous role in in vivo erythropoi-
esis, we transplanted BM from Rpl11+/+ and Rpl11+/lox donor
mice, both carrying the CreERT2 transgene, into irradiated
SCID mice. Transplanted mice acquired a normal profile of
mature T cells in the thymus, which was in contrast to non-trans-
planted SCID mice, thereby demonstrating successful BM
reconstitution (data not shown). BM-transplanted (BMT) SCID
mice were treated with continuous TAM diet, and we confirmed
the presence of the excised Rpl11lox allele (Rpl11D) in the BM
(Figure S4B). We refer to these transplanted mice and their
controls as TAM-BMT-Rpl11+/lox and TAM-BMT-Rpl11+/+
mice, respectively. Interestingly, RBC and hemoglobin levels
decreased over time in TAM-BMT-Rpl11+/lox animals compared
to TAM-Rpl11+/+ BMT controls (Figure 4A). Remarkably, histo-
logical analysis of the BM indicated a severe decrease in eryth-
roblasts (Figure 4B). Accordingly, TAM-BMT-Rpl11+/lox animals
showed visible signs of weakness and paleness (Figure S4C).
These observations indicate that RPL11 plays an important
and cell-autonomous role in erythropoiesis.
Rpl11 Is Involved in Erythroid Maturation
Having demonstrated that Rpl11 heterozygosity reduces the to-
tal number of erythroblasts, we wondered whether it also(C) Erythropoietin (Epo) mRNA levels measured by qRT-PCR in kidneys from
TAM-treated animals. Data correspond to the same mice as in (B). b-actin
mRNA levels are used as an endogenous control.
Values correspond to the average ± SD. Statistical t test analysis was per-
formed to calculate significance (*p% 0.05; **p % 0.01). For (A), see legend.
See also Figure S3.
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Figure 4. Intrinsic Hematopoietic Role of
RPL11 in Anemia
(A) RBC and hemoglobin values from TAM-BMT-
Rpl11+/+ and TAM-BMT-Rpl11+/lox animals are
shown along weeks in TAM diet. Data correspond
to ten to 15 (Rpl11+/+) or ten to 16 (Rpl11+/lox) TAM-
BMT animals, coming from four different donors
for each genotype.
(B) Representative images of histological sections
of bone marrows from TAM-BMT-Rpl11+/+ and
TAM-BMT-Rpl11+/lox animals stained with H&E
(upper) or with an antibody against TER119 (bot-
tom). Scale bars, 400and200mm in the left and right
images, respectively, for each genotype. Quantifi-
cation of the positive area for nucleated cells ex-
pressing TER119 is shown. Data correspond to
eight BM-transplanted animals per genotype
(coming from two BM donors, for each genotype).
(C) Quantification by flow cytometry of the per-
centage of erythroid cells from BMs of TAM-BMT-
Rpl11+/+ and TAM-BMT-Rpl11+/lox animals in the
different stages of erythroid maturation. Regions
are defined based on the expression pattern of
CD71 and TER119 markers. Data correspond to
eight BM-transplanted animals per genotype
(coming from two BM donors, for each genotype).
(D) Cell cycle analysis by flow cytometry after EdU
incorporation and Hoechst staining of total fetal
livers from Rpl11+/+ and Rpl11+/lox embryos (E14.5)
after daily injection of 4OHT in pregnant females
from E11.5 to E13.5.
(E) mRNA levels of Cdkn1a and Bax genes in the
different populations of erythroid progenitors from
Rpl11+/+ and Rpl11+/lox fetal livers, as in (D). mRNA
levels are normalized to b-actin levels.
Values correspond to the average ±SD. Statistical t
test analysis was performed to calculate signifi-
cance (*p % 0.05; **p % 0.01; ***p % 0.005). See
also Figure S4.impinges on erythroid maturation. Erythroid maturation can be
divided in five stages (RI to RV) based on the patterns of
TER119 signal (low or high) and CD71 signal (low, medium, or
high) measured by fluorescence-activated flow cytometry
(FACS) (Zhang et al., 2003a). We monitored erythroid matura-
tion in the BM of transplanted animals (TAM-BMT-Rpl11+/+
and TAM-BMT-Rpl11+/lox). Interestingly, we detected a signifi-
cant relative increase in the percentage of RI cells (primitive
progenitors and proerythroblasts) together with a decrease in
the more matured stages (RIII, RIV, and RV) (Figure 4C). Similar
findings were made in the BM of whole-body TAM-Rpl11+/lox
adult mice (Figure S4D), and in Rpl11+/lox fetal livers of TAM-
pregnant mothers (Figure S4E). The fact that fetal livers (which
are very active in erythropoiesis) manifest defective erythropoi-
esis prompted us to isolate erythroid progenitors and measure
proliferation by FACS (using 5-ethynyl-2’-deoxyuridine [EdU]716 Cell Reports 13, 712–722, October 27, 2015 ª2015 The Authorsincorporation and Hoechst staining).
Interestingly, as it was the case of fibro-
blasts (see Figure 1E), fetal liver cells
also showed evidence of lower prolifera-
tion (significant increase in cells at G1,and tendency to decrease cells in S) (Figure 4D). Stage RIII
erythroid precursors are the most abundant in fetal livers at
E14.5 (see, for example, Figure S4E), and we also observed a
significant G1 increase in RIII erythroid progenitors from fetal
livers (Figure S4F). We wondered whether we could detect
changes in candidate genes that could account for the impaired
erythropoiesis. In particular, we focused on the cell-cycle inhib-
itor Cdkn1a and on the pro-apoptotic factor Bax, which have
been previously found upregulated in human erythroid cells
and in zebrafish embryos with RPL11 deficiencies (Danilova
et al., 2011; Moniz et al., 2012). Interestingly, several popula-
tions of erythroid progenitors from Rpl11+/lox fetal livers pre-
sented a significant upregulation of Cdkn1a and Bax (Figure 4E).
We conclude that the partial loss of Rpl11 impairs erythroid
maturation, recapitulating the same cellular defects as in hu-
man DBA.
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Figure 5. Impact of Rpl11 Deficiency on the Transcriptional Profile of Bone Marrow Hematopoietic Progenitors
(A) Heatmap displaying differentially expressed genes (DEGs with FDR <0.15) as estimated by RNA-seq from Rpl11+/+ and Rpl11+/lox hematopoietic progenitor
cells (Lin-Sca1-cKIT+) of TAM-treated animals (n = 4 animals per genotype; 20 weeks of TAM treatment). Gene symbols are shown and relative expression
(log2FC) is scaled in color code (indicated), from dark blue (3) to dark red (3).
(B) Validation by qRT-PCR of some DEGs found in (A). Fold change over Rpl11+/+ is shown for each gene. Data correspond to the average ± SD of three to four
animals per genotype. Statistical t test analysis was performed to calculate significance (*p% 0.05; **p% 0.01).
(C) Enrichment plots for gene sets related to eukaryotic translation, DNA replication/cell cycle, and DNA repair pathways.
(D) Enrichment plots for gene sets related to MYC, MYB, and TGF-b.
In all the enrichment plots,Rpl11+/lox samples are located to the left. FDR and the number of genes per gene set (n) are indicated in each enrichment plot. See also
Figure S5 and Tables S1 and S2.Altered Transcriptional Profile Associated with Rpl11
Deficiency
To further understand the molecular consequences of Rpl11
deficiency, we performed an RNA-seq-based transcriptional
profiling of the BM hematopoietic progenitors (HPCs; Lin-
Sca1-cKIT+) in TAM-Rpl11+/lox mice and in their corresponding
TAM-Rpl11+/+ controls (n = 4 per genotype). Previous to this,
we confirmed that HPCs from TAM-Rpl11+/lox mice had lower
levels of Rpl11 mRNA than TAM-Rpl11+/+ control HPCs (Fig-
ure S5A). Analysis of the RNA sequencing (RNA-seq) data
revealed a number of differentially expressed genes (false dis-
covery rate [FDR] <0.15) (Figure 5A; Table S1). In agreement
with the impaired erythropoiesis observed in TAM-Rpl11+/loxCmice, genes related to erythrocyte development and function,
such as Uros, Gypa, Aqp1, Sphk1, Rhd, Cd82, Hebp1, and
Hba-a2, were among the genes significantly downregulated in
TAM-Rpl11+/lox HPCs (Figure 5A). By qRT-PCR, we confirmed
that some of these genes were downregulated inRpl11-deficient
HPCs (Figure 5B) but were unaffected in other tissues, such as
liver (Figure S5B). Other genes with diverse functions, such as
cathepsin E (Ctse), which promotes proteolysis, or claudin 13
(Cldn13), which has a structural function, were also downregu-
lated in Rpl11+/lox HPCs (Figures 5A and 5B). A description of
other downregulated genes is shown in Table S1. Regarding
the genes upregulated in TAM-Rpl11+/lox HPCs, we validated
the cyclin-dependent kinase inhibitor p21 (Cdkn1a) and a geneell Reports 13, 712–722, October 27, 2015 ª2015 The Authors 717
Figure 6. Rpl11 Deficiency Increases Sus-
ceptibility to Lymphomagenesis in g-Irradi-
ated Mice
(A) Kaplan-Meyer survival curve for g-irradiated
Rpl11+/+ and Rpl11+/lox mice fed TAM diet. Log-
rank (Mantel-Cox) test was performed to calculate
significance (*p% 0.05).
(B) Pictures of g-irradiated TAM-Rpl11+/lox mice
displaying thymic tumors.
(C) Immortalized Rpl11+/+, Rpl11+/lox, and
Rpl11lox/lox MEFs, all bearing the Tg.hUbC-
CreERT2 transgene, were treated with 4OHT for
3 days and then incubated with the following
drugs: ActD, for 6 hr, at the indicated concentra-
tions or 5 nM when not specified; CX5461, for
16 hr, at the indicated concentrations; or doxoru-
bicin, for 6 hr, at 0.5 mM. Levels of the indicated
proteins were measured by immunoblotting.
(D) Primary Rpl11+/+ and Rpl11lox/lox MEFs, all
carrying the Tg.hUbC-CreERT2 transgene, were
treated with 4OHT for the indicated times and
harvested for protein extraction. Levels of the
indicated proteins were measured by immuno-
blotting. The assay is representative of a total of
two assays with different MEF preparations.
(E) Representative histological sections stained for
cMYC from thymuses of Rpl11+/+ and Rpl11+/lox
mice (after 20 weeks of TAM diet). Scale bars, 100
(top images) and 50 (zoom in images) mm. Quan-
tification of cMYC-positive area is shown below.
Data correspond to the average ± SD of four in-
dependent animals per genotype. Statistical t test
analysis was performed to calculate significance
(*p% 0.05).
(F) Representative histological sections of bone
marrow stained for cMYC from TAM-BMT-
Rpl11+/+ and TAM-BMT-Rpl11+/lox mice.
Scale bars, 200 (top images) and 50 (zoom in im-
ages) mm. Pictures are representative of a total of
n = 4 per genotype. See also Figure S6.(9030617O03Rik) of unknown function (Figures 5A and 5B). Gene
set enrichment analysis (FDR <0.25) showed that several
transcriptional gene sets related to eukaryotic translation
(including the gene set ‘‘Ribosome’’) were downregulated in
TAM-Rpl11+/lox HPCs (Figure 5C; Table S2). A high number of
gene sets involved in DNA replication/cell cycle and DNA repair
were also downregulated (Figure 5C; Table S2). We found partic-
ularly interesting that potentially oncogenic pathways were upre-
gulated, such as MYC and MYB transcription networks and
transforming growth factor b (TGF-b) signaling pathway (Fig-
ure 5D; Table S2). Remarkably, a very recent report has showed
upregulation of the TGF-b signaling pathway in induced pluripo-
tent stem cells derived from DBA patients with mutations in
RPS19 or RPL15 (Ge et al., 2015).
Partial Loss of Rpl11 Favors Lymphomagenesis
Patients with ribosomopathies, including those with DBA, are
prone to develop cancer, often of hematological origin, although
the mechanisms involved are poorly understood (Narla and718 Cell Reports 13, 712–722, October 27, 2015 ª2015 The AuthorsEbert, 2010; Teng et al., 2013). To address this issue, we tested
whether partial loss of Rpl11 predisposed mice to lymphoma-
genesis. We irradiated mice with a single dose of 5 Gy, and, after
1 week, we fed them with tamoxifen (abbreviated as gIR-TAM
mice). As expected from our above-described findings, gIR-
TAM-Rpl11+/lox mice developed anemia, as measured by the
red blood numbers and hemoglobin blood content (Figure S6A).
Remarkably, gIR-TAM-Rpl11+/lox mice died significantly earlier
than control TAM-Rpl11+/+ mice (Figure 6A). Upon necropsy,
gIR-TAM-Rpl11+/lox mice presented lymphomas, particularly in
the thymus, which in some cases occupied most of the thoracic
cavity (Figure 6B). These observations demonstrate that partial
loss of Rpl11 predisposes to lymphomagenesis.
Rpl11 Deficiency Affects p53 Response and cMYC
Levels
Based on previous literature, two conceivable and non-exclusive
mechanisms could explain the observed susceptibility to cancer
upon partial loss of Rpl11. In particular, ribosome-free RPL11
acts as a sensor of ribosome unbalance by activating p53 (Bhat
et al., 2004; Bursac et al., 2012; Donati et al., 2013; Horn and
Vousden, 2008; Lohrum et al., 2003; Zhang et al., 2003b) and
by inhibiting cMYC (Challagundla et al., 2011; Dai et al., 2007,
2010). To evaluate the p53 response to ribosomal stress, we
treated MEFs of the three relevant genotypes (all bearing the
Tg.UbC-CreERT2 transgene) with 4OHT for 3 days followed by
low doses of actinomycin D (ActD), which is a well-established
method to induce ribosomal stress (Burger et al., 2010). In addi-
tion to this, we used an RNA polymerase I inhibitor, CX5461,
which activates p53 in an RPL11-dependent manner and has
shown promising pre-clinical anti-tumoral activity (Bywater
et al., 2012; Drygin et al., 2011). Finally, we also tested the radio-
mimetic agent doxorubicin (Doxo), which in addition to DNA
damage also induces ribosomal stress (Burger et al., 2010; Lla-
nos and Serrano, 2010; Zhu et al., 2009). Importantly, the stabi-
lization of p53 in response to all these agents (ActD, CX5461,
Doxo) was severely impaired in 4OHT-Rpl11lox/lox cells, and it
was partially compromised in 4OHT-Rpl11+/lox cells (Figure 6C).
Regarding cMYC, previous investigators have reported that
downregulation of RPL11 in cultured cancer cells results in
increased levels of cMYC protein (Challagundla et al., 2011;
Dai et al., 2007, 2010). In this regard, we have observed above
that Rpl11 heterozygous HPCs present an upregulation of
MYC gene sets (see above Figure 5D). Based on this, we
wondered whether reduced gene dosage of Rpl11 could have
an impact on the levels of cMYC. First, we examined cMYC
levels in primary 4OHT-Rpl11+/+ and 4OHT-Rpl11lox/lox MEFs.
In support of the above-mentioned evidences, cMYC protein
levels were increased inRpl11lox/lox MEFs upon 4OHT treatment,
whereas cMYC levels remained unchanged in Rpl11+/+ MEFs
(Figure 6D). Also, immunohistochemical staining of cMYC
showed a clear and reproducible increase in cMYC levels in
the thymus of TAM-Rpl11+/lox mice compared to TAM-Rpl11+/+
controls (Figure 6E). Of note, we confirmed that TAM treatment
was effective in reducing (by 40%) the levels of Rpl11 mRNA in
the thymus (Figure S6B). Similar observations regarding cMYC
protein levels were made in the spleen of TAM-Rpl11+/lox mice
(Figure S6C) and in the BM of TAM-BMT-Rpl11+/lox transplanted
animals (Figure 6F). Therefore,Rpl11 deficiency, even in the form
of Rpl11 heterozygosity, compromises p53 function and in-
creases cMYC protein basal levels. These two pro-tumorigenic
effects could contribute, alone or combined, to the cancer sus-
ceptibility of Rpl11-deficient mice.
DISCUSSION
In this work, we have set to generate amousemodel of Diamond-
Blackfan anemia (DBA) based on the deficiency of the ribosomal
protein RPL11. A first remarkable observation is the fact that em-
bryonic heterozygous deletion of Rpl11 is lethal, implying that
diploid levels of RPL11 are required for embryonic development.
This is an unusually extremephenotype formicewith deficiencies
in ribosomal proteins (Caldarola et al., 2009), and we are only
aware of one other ribosomal gene, RpS6, that is embryonically
lethal in heterozygosity (Panic et al., 2006). Also, inducible com-
plete deletion of Rpl11 in adult mice was lethal within 8 weeks
post-deletion, probably due to intestinal atrophy, and it wasCaccompanied by bone marrow aplasia and erythropoietic de-
fects. This severe phenotype is not surprising given the essential
role of RPL11 in the formation and function of ribosomes. Human
DBA patients carry heterozygous loss-of-function mutations in
ribosomal genes (Boria et al., 2010; Cmejla et al., 2009; Gazda
et al., 2008; Quarello et al., 2010). For this reason, and consid-
ering the embryonic lethality of constitutively heterozygous
mice, we have focused our work on the effects of inducible het-
erozygous deletion of Rpl11 in adult mice.
A number of mousemodels of DBA and ribosomopathies have
been reported (McGowan and Mason, 2011; Narla and Ebert,
2010), but only a subset of them recapitulate the erythropoietic
defect characteristic of human DBA patients, namely, mice
with partial deficiencies of Rps19 (Devlin et al., 2010; Jaako
et al., 2011), Rps6 (Keel et al., 2012; McGowan et al., 2011), or
Rps14 (Barlow et al., 2010). Similar to these mouse models, we
show that inducible heterozygous deletion of Rpl11 produces a
non-lethal anemia characterized by a severe reduction of eryth-
roblasts in the bonemarrow. In addition, the erythroblasts of het-
erozygous Rpl11 mice present a maturation defect, which is
accompanied by upregulation of the cell-cycle inhibitor Cdkn1a
and the pro-apoptotic factor Bax. In relation to this, erythroid
progenitors from peripheral blood of RPL11-mutated human
DBA patients present a similar erythroid differentiation defect
with upregulation of CDKN1A (Moniz et al., 2012). In addition,
we have observed that a number of genes involved in erythrocyte
differentiation are downregulated in heterozygous Rpl11 he-
matopoietic progenitors. Together, these observations could
explain, at least in part, the reduced number of erythroblasts
and their defective maturation in Rpl11-deficient mice.
Besides the severe defect in erythropoiesis, heterozygous
Rpl11mice did not have other noticeable defects in the hemato-
poietic lineage, presenting normal levels of hematopoietic stem
cells and early progenitors, B cell subpopulations, and T cell sub-
populations. Despite the apparently normal production of non-
erythroid lineages, the analysis of the gene expression profile
of Rpl11 heterozygous hematopoietic progenitors showed an
upregulation of the cell-cycle inhibitor geneCdkn1a and downre-
gulation of a number of mitotic and cell-cycle gene sets.
Compared to other hematopoietic progenitors, erythroblasts
are highly proliferative, and this could render themmore suscep-
tible to a partial reduction in proliferation. Furthermore, normal
mice transplanted with inducible heterozygous Rpl11 bone
marrow also developed anemia and reduced number of erythro-
blasts upon induction of Rpl11 deletion. Together, these obser-
vations suggest that erythropoiesis critically relies on diploid
levels of RPL11. A similar situation is encountered in DBA pa-
tients, where haploid levels of a given ribosomal gene selectively
affect erythropoiesis (Narla and Ebert, 2010).
In addition toanemia,DBApatients are alsocharacterizedbyan
increased susceptibility to cancer (Ruggero and Shimamura,
2014); however, tumor susceptibility in mouse models of DBA
has remained largely unexplored until now. We have observed
that heterozygous Rpl11 mice are highly susceptible to develop
radiation-induced lymphomas. This phenotype is apparently par-
adoxical given the fact that an impaired ribosome production
should limit cell growth and proliferation; however, it could reflect
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suppression. In particular, ribosome-free RPL11 acts as a sensor
of ribosome unbalance by activating p53 (Bhat et al., 2004; Loh-
rumetal., 2003;Zhangetal., 2003b) andby inhibitingcMYC (Chal-
lagundla et al., 2011; Dai et al., 2007, 2010). In mouse embryo fi-
broblasts, we have observed that complete or partial deletion of
Rpl11 impairs the activation of p53 by ribosomal stress and by
DNAdamage.Also, fibroblasts,bonemarrow, spleen, and thymus
of heterozygous Rpl11 mice present increased basal levels of
cMYC protein. Therefore, both mechanisms, namely, impaired
p53 response and increased cMYC levels, can conceivably ac-
count for the observed tumor-prone phenotype of heterozygous
Rpl11mice. As a marginal note, the upregulation of cMYC could
also contribute to the impaired erythroid differentiation phenotype
(Acosta et al., 2008; Coppola and Cole, 1986; Geiler et al., 2014).
In summary, we have generated and characterized a mouse
model of DBA based on heterozygous deficiency of Rpl11.
These mice recapitulate the two main features of DBA, namely,
anemia and cancer susceptibility. In the case of anemia, we
have identified a defect in erythroid differentiation associated
with the upregulation ofCdkn1a andBax in erythroid progenitors.
Regarding tumor susceptibility, we present supporting data for
two non-exclusive mechanisms based on the known capacity
of ribosome-free RPL11 to activate p53 and inhibit cMYC. This
mouse model may help to further understand DBA and to test
possible therapeutic approaches.
EXPERIMENTAL PROCEDURES
Generation of a Conditional Rpl11 Knockout Mouse Model
A DNA construct with exons 3 and 4 of the Rpl11 gene flanked by loxP sites
and bearing a neomycin cassette (flanked by FRT sites) in intron 2 was gener-
ated by GeneBridges and electroporated in G4 embryonic stem (ES) cells
(C57BL/6Ncr3 129S6/SvEvTac) at the CNIO Transgenic Mice Unit. Recombi-
nant ES clones were selected by neomycin resistance and screened for inser-
tion of the construct in the 50 and 30 homology arms of the chromosome 4 by
Southern blot and long-range PCR, respectively. The presence of both loxP
sites was confirmed by PCR. One positive clone was aggregated with albino
ES cells (B6(Cg)-Tyrc-2J/J) and injected into pseudo-pregnant albino females.
A 100%male chimera was then mated with CD-1 females in order to check for
the germline transmission and establish the mouse colony. Mice bearing the
neomycin (Neo) resistance gene (Rpl11+/loxfrt) were viable and fertile and
crossed with B6 mice expressing a flipase recombinase (pCAG-Flpe) (Rodrı´-
guez et al., 2000), which recognizes the FRT sites and excises the Neo
cassette. Rpl11+/lox mice were mated with either constitutive (Tg.pCAG-Cre)
(Sakai and Miyazaki, 1997) or with inducible (Tg.hUbC-CreERT2) (Ruzankina
et al., 2007) Cre expressing mice (all in B6 background). The mice used for
this work are in a mixed background (81.25% B6: 6.25% 129Sv: 12.5%
CD1). All animals were maintained at the Spanish National Cancer Research
Centre (CNIO) under specific pathogen-free conditions, in agreement with
the recommendations of the Federation of European Laboratory Animal Sci-
ence Association (FELASA). Mice were fed a standard chow diet ad libitum.
When indicated, standard chow diet was replaced by tamoxifen diet (Teklad,
Harlan Laboratories) to induce activation of the CreERT2 transgene. All animal
procedures were evaluated and approved by the Ethical Committee of the
Carlos III Health Institute, Madrid, Spain (#54-2013-v2).
Cell Culture and Treatments
MEFs were isolated from embryos at day E13.5 and cultured in DMEM (Gibco)
supplemented with 10% fetal bovine serum (Gibco) and 100 U/ml penicillin-
streptomycin (Gibco) in a humidified atmosphere at 37C, 5%CO2. For immor-
talization, cells were infected with a retroviral vector expressing T121, a
truncated form of the SV40 large T antigen (Sa´enz Robles et al., 1994) and
underwent antibiotic selection. Where indicated, cells were treated with720 Cell Reports 13, 712–722, October 27, 2015 ª2015 The Authors1 mM 4-hydroxytamoxifen (4OHT; Sigma H7904), actinomycin D (Sigma),
CX5461 (Selleckchem), or doxorubicin (Sigma).
Nuclear/Cytosolic Fractionation
Immortalized MEFs were harvested and nuclear and cytosolic fractions were
obtained by using the NE-PER Nuclear and Cytoplasmic Extraction Kit by
Thermo Scientific, following the manufacturer’s instructions.
Red Blood Cells and Hemoglobin Monitoring
Blood was obtained from submaxillary bleeding, and red blood cell counts,
mean corpuscular volume, (MCV) and hemoglobin levels were measured in
an Abacus Junior Vet Hematology Analyzer.
Bone Marrow Transplantation
Bone marrows (BMs) from animals 6–8 weeks old were isolated by flushing fe-
murs and tibias (RPMI medium supplemented with 15% fetal bovine serum
[FBS] and Pen/Strep) with a 25-G syringe, followed by disaggregation with a
21-G syringe and subsequent filtration through a 70-mm nylon mesh. Erythro-
cytes were lysed in ammonium chloride (STEMCELL Technologies) for 5min at
room temperature, neutralized with fresh medium, and counted. A total of 2.5–
5 millions of cells in Leibovitz medium were injected by tail vein in immunode-
ficient SCID recipient mice (CB17/Icr-Prkdcscid/Crl) of 10–12 weeks old. SCID
mice were irradiated with a single dose of 3.5 Gy the day before to BM
transplantation.
Isolation of Fetal Liver Cells
Pregnant females were intraperitoneally (i.p.) injected with 4OHT (Sigma,
H6278), 2 mg/day dissolved in corn oil, for 3 days before fetal livers collection
at E14.5. Fetal livers were disaggregated with a 25-G syringe in RPMI medium
(supplemented with 15% FBS and Pen/Strep) and passed through a 40-mm
nylon mesh. Erythrocytes were lysed in ammonium chloride (Stemcell Tech-
nologies) for 5 min at room temperature, and cells were counted and
processed for flow cytometry. For cell-cycle analysis, fetal liver cells were
incubated ex vivo with EdU (10 mM) for 30 min and then stained with the
anti-TER119 and anti-CD-71 antibodies for flow cytometry. EdU was labeled
through covalent binding to Alexa Fluor 647 azide using Click-iT chemistry
(Invitrogen) following manufacturer’s instructions. DNA was stained with
Hoechst. Quantification of the different cell-cycle phases was performed in
the total liver cells or in the various erythroid progenitor populations according
to TER119 and CD-71 stainings.
Flow Cytometry
Cells were isolated by flushing (BM) or disaggregating tissues (spleen and
thymus) followed by filtering through a nylonmesh and removal of erythrocytes
by ammonium chloride lysis. 2.5–5 million cells were then blocked in a solution
containing Fc block (CD16/CD32, BD Biosciences #553141) in a 1:400 dilution
and incubated with the following conjugated antibodies for 30 min to 1 hr in ice
(spleen and thymus) or at room temperature (BM cells): mouse hematopoietic
lineage eF450 cocktail (eBioscience #88-7772-72), Sca-1-PerCP/Cy5.5 (eBio-
science #45-5981-80), cKIT-APC/H7 (BD Biosciences #560250), CD34-eF660
(eBioscience #50-0341-82), IL7R-AF488 (eBioscience #53-1271-82), FcgRIII/II
(CD16/32)-PE/Cy7 (eBioscience #25-0161-81), CD71-PE (eBioscience #12-
0711-83) and TER119-FITC (eBioscience #11-5921-82). Fluorescence Minus
One (FMO) was used to gate cell populations and commercial anti-mouse or
anti-rat Igk beads (BD Biosciences #552843 or # 552844) to compensate for
fluorochrome spectral overlap during flow cytometry. Cells were analyzed in
an LSR-Fortessa or FACS CANTO (BD Biosciences; FACS Diva software).
Data were analyzed with FlowJo 9.6.2 software.
RNA-Seq-Based Transcriptional Profiling
RNA was prepared by using Direct-zol (Zymo Research) from BM hematopoi-
etic progenitor cells (Lin- Sca1– cKIT+) of TAM-treated animals. Mouse lineage
depletion cocktail (Miltenyi #130-090-858) was used to eliminate mature he-
matopoietic cells. RNA Integrity Number (RIN) was in the range 7.5–9.3 (Agilent
2100 Bionalyzer). 2–8 ng of total RNA was used to synthesize the cDNA
(SMARTer Ultra Low Input RNA Kit, version 3, Clontech #634848). After ampli-
fication with SeqAmp DNA Polymerase (Clontech), 10 ng of cDNA was used
to prepare the adaptor-ligated library following the ‘‘TruSeq DNA sample prep-
aration guide’’ (part #15005180). The resulting cDNA libraries were sequenced
for 50 bases in a single-read format (Illumina HiSeq2000). Reads were aligned
to the mouse genome (GRCm38/mm10) with TopHat-2.0.10 (Trapnell et al.,
2012) using Bowtie 1.0.0 (Langmead et al., 2009) and Samtools 0.1.19 (Li
et al., 2009), allowing two mismatches and five multihits. Transcripts assem-
bly, estimation of their abundances and differential expression were calculated
with Cufflinks 2.2.1 (Trapnell et al., 2012), using the mouse genome annotation
data set GRCm38/mm10 from the UCSC Genome Browser. Gene Set Enrich-
ment Analysis (GSEA) was performed using annotations from the KEGG,
Reactome and NCI databases. Genes were ranked using the t statistic. After
Kolmogorov-Smirnoff correction for multiple testing, only those pathways
bearing a FDR <0.25 were considered significant. Enrichment plots were
also obtained with GSEA and ranked according to their enrichment score (ES).
Histopathology
Mice organs were fixed in formalin and embedded in formalin/paraffin blocks.
Sections and H&E and immunohistochemistry stainings were performed by
the CNIO Histopathology Unit. Antibodies recognizing TER119 (BD Biosci-
ences, #550565) and c-MYC (Abcam, clone Y69, #ab32072) were used.
Positive cells for the above mentioned antibodies were quantified by using
AxioVision (Zeiss) software.
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